How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
hyperprogressive disease
immune checkpoint inhibitors
predictive factors
solid tumor
tumor growth
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
12
2019
accepted:
03
03
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
30
3
2021
Statut:
epublish
Résumé
Following the administration of immune checkpoint inhibitors, an unexpected pattern of response designated as hyperprogression may be observed in certain patients. This paradoxical response corresponds to an acceleration in tumor growth and a dramatic decrease of patient survival. The reported incidence rates of hyperprogressive disease are highly variable, ranging between 4 and 29%. In this review, we have performed a literature search on hyperprogressive disease, including both retrospective studies and case reports, and discuss potential predictive biomarkers as well as potential mechanisms associated with immune-checkpoint inhibitor associated hyperprogression.
Identifiants
pubmed: 32265935
doi: 10.3389/fimmu.2020.00492
pmc: PMC7098964
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
492Informations de copyright
Copyright © 2020 Denis, Duruisseaux, Brevet and Dumontet.
Références
Lung Cancer. 2017 Nov;113:4-6
pubmed: 29110847
Semin Oncol. 2015 Oct;42 Suppl 2:S19-28
pubmed: 26477471
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
Nat Rev Clin Oncol. 2013 Oct;10(10):588-98
pubmed: 23982524
Int Immunopharmacol. 2018 May;58:125-135
pubmed: 29579717
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Cancer. 2017 Apr 1;123(7):1259-1271
pubmed: 27906454
J Clin Oncol. 1995 May;13(5):1123-8
pubmed: 7537797
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Mol Cancer Ther. 2019 Feb;18(2):448-458
pubmed: 30523049
Immunotherapy. 2019 Feb;11(3):167-175
pubmed: 30730278
Gynecol Oncol. 2019 Feb;152(2):251-258
pubmed: 30470581
Cancer Immunol Res. 2013 Aug;1(2):92-8
pubmed: 24777500
Mol Immunol. 2019 Jun;110:48-56
pubmed: 29174430
Cancer Res. 2017 Mar 1;77(5):1083-1096
pubmed: 28082403
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
Lung Cancer. 2019 Apr;130:128-134
pubmed: 30885333
Semin Immunopathol. 2019 Jan;41(1):31-40
pubmed: 29968044
J Immunother Cancer. 2016 Dec 20;4:92
pubmed: 28031820
Lancet Respir Med. 2018 Oct;6(10):771-781
pubmed: 30100403
J Thorac Oncol. 2018 Oct;13(10):e193-e196
pubmed: 29775806
Gastric Cancer. 2019 Jul;22(4):793-802
pubmed: 30627987
Cancers (Basel). 2017 May 11;9(5):
pubmed: 28492495
World J Urol. 2018 Nov;36(11):1703-1709
pubmed: 29549485
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
J Exp Med. 1981 Jun 1;153(6):1533-46
pubmed: 6454751
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
BMC Cancer. 2019 Jul 17;19(1):705
pubmed: 31315610
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
BMJ Case Rep. 2017 May 12;2017:
pubmed: 28500114
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Cancer Treat Rev. 2018 Nov;70:16-21
pubmed: 30053725
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Exp Med. 2013 May 6;210(5):917-31
pubmed: 23589566
Cancer Immunol Res. 2016 Mar;4(3):179-82
pubmed: 26701266
Front Immunol. 2018 Oct 09;9:2100
pubmed: 30356816
Oncogenesis. 2018 May 25;7(5):41
pubmed: 29799520
Nat Commun. 2015 Sep 23;6:8280
pubmed: 26395069
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Clin Cancer Res. 2019 Feb 1;25(3):904-906
pubmed: 30397179
Front Immunol. 2018 Apr 19;9:797
pubmed: 29725330
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Cancers (Basel). 2017 Jan 27;9(2):
pubmed: 28134806
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
JCO Precis Oncol. 2018;2018:
pubmed: 30148248
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Cancer Biol Ther. 2019;20(1):6-7
pubmed: 30332546
J Transl Med. 2013 Mar 03;11:54
pubmed: 23452415
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
iScience. 2018 Nov 30;9:258-277
pubmed: 30439581
Immunology. 2008 Jan;123(1):40-4
pubmed: 18154618
Curr Opin Neurol. 2009 Dec;22(6):633-8
pubmed: 19770760